Literature DB >> 11981736

Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1?

Mina Hosseinipour1, Myron S Cohen, Pietro L Vernazza, Angela D M Kashuba.   

Abstract

Approximately 5 million people annually are newly infected with human immunodeficiency virus (HIV). Although education, behavior modification, and promotion of condom use are effective transmission-prevention measures, the severity of the pandemic demands that all possible prevention strategies be explored. Antiretroviral therapy has the potential to decrease sexual transmission of HIV type 1 by reducing levels of HIV RNA and thus decreasing the risk that infected persons will transmit the disease or by its use as preexposure or postexposure prophylaxis. In this article, we explore the rationale for using antiretroviral therapy to prevent sexual transmission of HIV, as well as the limitations of this approach.

Entities:  

Mesh:

Year:  2002        PMID: 11981736     DOI: 10.1086/340403

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  22 in total

1.  Antiretroviral therapy as HIV prevention: status and prospects.

Authors:  Kenneth H Mayer; Kartik K Venkatesh
Journal:  Am J Public Health       Date:  2010-08-19       Impact factor: 9.308

2.  The Evolving Role of HIV Counseling and Testing in Resource-limited Settings: HIV Prevention and Linkage to Expanding HIV Care Access.

Authors:  Cheryl A Liechty
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

Review 3.  The evolving role of HIV counseling and testing in resource-limited settings: HIV prevention and linkage to expanding HIV care access.

Authors:  Cheryl A Liechty
Journal:  Curr HIV/AIDS Rep       Date:  2004-12       Impact factor: 5.071

Review 4.  Does antiretroviral therapy prevent HIV transmission to sexual partners?

Authors:  Tahaniyat Lalani; Charles Hicks
Journal:  Curr HIV/AIDS Rep       Date:  2007-05       Impact factor: 5.071

5.  Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.

Authors:  Julie B Dumond; Rosa F Yeh; Kristine B Patterson; Amanda H Corbett; Byung Hwa Jung; Naser L Rezk; Arlene S Bridges; Paul W Stewart; Myron S Cohen; Angela D M Kashuba
Journal:  AIDS       Date:  2007-09-12       Impact factor: 4.177

6.  Does antiretroviral therapy prevent HIV transmission to sexual partners?

Authors:  Tahaniyat Lalani; Charles Hicks
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

Review 7.  Integrating HIV prevention activities into the HIV medical care setting: a report from the NYC HIV Centers Consortium.

Authors:  Tracey E Wilson; David Vlahov; Stephen Crystal; Judith Absalon; Susan J Klein; Robert H Remien; Robert H Remein; Bruce Agins
Journal:  J Urban Health       Date:  2006-01       Impact factor: 3.671

8.  How HIV treatment could result in effective prevention.

Authors:  Kartik K Venkatesh; Mark N Lurie; Kenneth H Mayer
Journal:  Future Virol       Date:  2010-07       Impact factor: 1.831

Review 9.  Addressing research priorities for prevention of HIV infection in the United States.

Authors:  Sten H Vermund; Sally L Hodder; Jessica E Justman; Beryl A Koblin; Timothy D Mastro; Kenneth H Mayer; Darrell P Wheeler; Wafaa M El-Sadr
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

10.  Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection.

Authors:  Jasmine A Talameh; Naser L Rezk; Angela D M Kashuba
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-01-01       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.